Interview Series 20th March 2026
From the helm: Alterity Therapeutics (ASX:ATH), CEO, David Stamler.
In this episode of From the Helm, Grady chats with Alterity Therapeutics (ASX:ATH) CEO David Stamler, to discuss their neurodegenerative disorder treatment specifically targeting Multiple System Atrophy (MSA), a rare and aggressive disease affecting involuntary functions and motor control.





_600_338.jpg)


-min_600_399.png)
-min_600_338.png)
_600_338.png)
